News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Boston Scientific Corporation (NYSE:BSX) is one of the Stocks Expected to Bounce Back According to Analysts. The stock has fallen more than 52% year-to-date, but the Street expects more than 65% upside from the current level. Recently, on June 16, TD Cowen analyst Josh Jennings maintained his Buy rating on Boston Scientific Corporation (NYSE:BSX) with […]
Boston Scientific Corp. (NYSE:BSX) is one of the 10 oversold stocks offering high upside. On June 12, Matt O’Brien from Piper Sandler reduced the target price on Boston Scientific Corporation (NYSE:BSX) from $90 to $65, resulting in an adjusted upside potential of close to 45% at the current level. The analyst retained an Overweight rating […]
Deal volumes and values are tracking above the first half of 2025, driven by Boston Scientific’s Penumbra buyout and Danaher’s Masimo acquisition.
Boston Scientific Corporation (NYSE:BSX) is among the 10 Most Oversold S&P 500 Stocks So Far in 2026. On May 29, Wolfe Research downgraded the stock from Outperform to Peer Perform. This marks the end of the firm’s bullish outlook on the stock for four years, with the adjustment coming after the company said sales growth […]
With a 5-year average revenue growth rate of 13.52%, Boston Scientific Corporation (NASDAQ:BSX) is included among the 11 Best Long Term US Stocks to Buy Right Now. On May 19, Baird lowered its price recommendation on Boston Scientific Corporation (NASDAQ:BSX) to $75 from $78. It reiterated an Outperform rating on the shares. The firm updated its model […]
Morningstar now rates Boston Scientific (BSX) as significantly undervalued after a meaningful share price decline. The firm is flagging the stock as a potential opportunity for investors who focus on gaps between price and estimated fair value. See our latest analysis for Boston Scientific. Recent governance updates, including the removal of supermajority voting provisions and fresh director equity awards, have coincided with a sharp reset in sentiment, with the 30 day share price return down...